Anderson Hoagland & Co. cut its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 43.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,926 shares of the company’s stock after selling 8,464 shares during the period. Anderson Hoagland & Co.’s holdings in Henry Schein were worth $764,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. YorkBridge Wealth Partners LLC boosted its position in shares of Henry Schein by 5.2% during the second quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock valued at $104,000 after buying an additional 28 shares during the last quarter. Sun Life Financial INC boosted its position in shares of Henry Schein by 8,185.7% during the second quarter. Sun Life Financial INC now owns 580 shares of the company’s stock valued at $106,000 after buying an additional 573 shares during the last quarter. FTB Advisors Inc. boosted its position in shares of Henry Schein by 100.0% during the third quarter. FTB Advisors Inc. now owns 1,484 shares of the company’s stock valued at $120,000 after buying an additional 742 shares during the last quarter. Trust Co. of Vermont boosted its position in shares of Henry Schein by 56.7% during the third quarter. Trust Co. of Vermont now owns 1,702 shares of the company’s stock valued at $140,000 after buying an additional 616 shares during the last quarter. Finally, Lee Financial Co boosted its position in shares of Henry Schein by 100.0% during the third quarter. Lee Financial Co now owns 1,756 shares of the company’s stock valued at $144,000 after buying an additional 878 shares during the last quarter. 91.70% of the stock is currently owned by institutional investors.
In other news, Director Barry J. Alperin sold 5,796 shares of Henry Schein stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the transaction, the director now directly owns 48,172 shares of the company’s stock, valued at approximately $3,408,650.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.19% of the stock is owned by insiders.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). The firm had revenue of $3.16 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.84 earnings per share. equities analysts forecast that Henry Schein, Inc. will post 3.6 earnings per share for the current year.
Several research firms recently commented on HSIC. Zacks Investment Research raised Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Royal Bank of Canada dropped their price objective on Henry Schein from $91.00 to $82.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 7th. Jefferies Group reaffirmed a “hold” rating and set a $89.00 price objective on shares of Henry Schein in a research report on Friday, October 20th. Stephens assumed coverage on Henry Schein in a research report on Tuesday, November 28th. They issued an “equal weight” rating and a $76.00 target price on the stock. Finally, Morgan Stanley cut Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 target price on the stock. in a research report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $84.23.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.